









Markets
/
Stocks
/
nasdaq-epix
/

ESSA Pharma Inc

EPIX

View Detailed Chart

1.880USD

0.000

Market hours （ET）Quotes delayed by 15 min

83.45MMarket Cap

LossP/E TTM



ESSA Pharma Inc

1.880

0.000

Overview Company Financials

Financials

Intraday

30m

Today

0.00%

5 Days

0.00%

1 Month

+8.05%

6 Months

+11.24%

Year to Date

+5.03%

1 Year

-60.17%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(2)

Neutral(3)

Buy(8)

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.001

Neutral

RSI(14)

65.242

Neutral

STOCH(KDJ)(9,3,3)

69.998

Neutral

ATR(14)

0.013

High Vlolatility

CCI(14)

172.337

Buy

Williams %R

33.333

Buy

TRIX(12,20)

0.383

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

1.876

Buy

MA10

1.873

Buy

MA20

1.832

Buy

MA50

1.753

Buy

MA100

1.703

Buy

MA200

1.990

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

Ticker SymbolEPIX

CompanyESSA Pharma Inc

CEODr. David Ross Parkinson, M.D.

Websitehttps://www.essapharma.com/